To profile the early antibody response in COVID-19 patients, we investigated the levels of neutralizing antibodies against authentic SARS-CoV-2 virus and IgG/IgM ELISAs against multiple antigens including the full-length spike (S), the spike RBD S and the N of SARS-CoV-2. The gene discussed is CD40LG; the disease is COVID-19.